Abstract
The treatment of non-small cell lung cancer (NSCLC) has become increasingly biomarker-driven over the last decade, with a growing number of targeted therapies available for patients with specific genomic alterations. A fast-track screening of multiple molecular biomarkers is therefore required for first-line treatment selection in NSCLC, although challenging considering both turnaround time and sample quality. In an effort to improve the molecular diagnostic workup at our institution, we implemented a two-step reflex test (RT) at the time of pathological diagnosis of non-squamous NSCLC for EGFR, KRAS, BRAF, ERBB2, ALK, ROS1, PDL-1, RET, MET, and NTRK testing.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
